{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:07:02Z","timestamp":1783937222683,"version":"3.55.0"},"reference-count":33,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Carbon-ion radiotherapy (CIRT) is an effective local treatment for hepatocellular carcinoma (HCC); however, evidence on systemic immunotherapy after CIRT and the role of CIRT following immunotherapy remains limited. This study aimed to assess clinical outcomes and sequencing of CIRT and systemic immunotherapy in real-world practice. Methods: We retrospectively analyzed 41 patients with HCC who received CIRT and systemic immunotherapy (atezolizumab plus bevacizumab or durvalumab plus tremelimumab). Patients were categorized into three groups: (i) systemic immunotherapy for recurrent HCC after CIRT (n = 20), (ii) curative-intent CIRT after systemic immunotherapy (n = 10), and (iii) CIRT for residual or insufficiently responding lesions (\u22643 lesions) after systemic immunotherapy (n = 11). Results: In group (i), 14 of 20 patients achieved complete or partial responses. These responders had low tumor burden (within the up-to-7 criteria) and preserved liver function (modified albumin\u2013bilirubin grade 1\/2a) at treatment initiation and demonstrated significantly longer progression-free and overall survival than those with stable or progressive disease. In group (ii), 4 of 10 patients achieved a clinical complete response and became drug-free; notably, all had solitary intrahepatic tumors at immunotherapy initiation. In group (iii), the rate of transition to clinical complete response was low, and disease control remained limited. Conclusions: Systemic immunotherapy demonstrated high effectiveness in recurrent HCC following CIRT, particularly in patients with low tumor burden and preserved liver function. Moreover, curative-intent CIRT after immunotherapy may benefit patients with solitary intrahepatic tumors but appears limited in those with insufficient response to immunotherapy, including residual oligolesions.<\/jats:p>","DOI":"10.3390\/jcm15145449","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:53:58Z","timestamp":1783932838000},"page":"5449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab Plus Tremelimumab): A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2035-1940","authenticated-orcid":false,"given":"Keita","family":"Maki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-1837","authenticated-orcid":false,"given":"Hiroaki","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hoshikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-7505","authenticated-orcid":false,"given":"Tomohiro","family":"Katsumi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-5094","authenticated-orcid":false,"given":"Yasuhito","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Koto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-4250","authenticated-orcid":false,"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata City 990-9585, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","article-title":"Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China","volume":"154","author":"Xu","year":"2019","journal-title":"JAMA Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1245\/s10434-016-5713-2","article-title":"Actual 10-year survivors after resection of hepatocellular carcinoma","volume":"24","author":"Zheng","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3350\/cmh.2020.0016","article-title":"Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients","volume":"26","author":"Kim","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_6","first-page":"e20230035","article-title":"Systemic therapy combined with locoregional therapy in intermediate-stage hepatocellular carcinoma","volume":"10","author":"Kudo","year":"2024","journal-title":"Interv. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4251\/wjgo.v15.i1.1","article-title":"Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma","volume":"15","author":"Liang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2147\/JHC.S292516","article-title":"Carbon ion radiotherapy in the management of hepatocellular carcinoma","volume":"8","author":"Abousaida","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shiba, S., Abe, T., Shibuya, K., Katoh, H., Koyama, Y., Shimada, H., Kakizaki, S., Shirabe, K., Kuwano, H., and Ohno, T. (2017). Carbon ion radiotherapy for 80-year-old or older patients with hepatocellular carcinoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3724-4"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Maki, K., Haga, H., Katsumi, T., Hoshikawa, K., Suzuki, F., Uchiyama, F., Kaneko, T., Koto, M., and Ueno, Y. (2025). Adverse events after carbon-ion radiotherapy (CIRT) for hepatocellular carcinoma and risk factors for biliary stricture after CIRT: A retrospective study. Cancers, 17.","DOI":"10.3390\/cancers17152542"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/JHC.S429186","article-title":"Pencil beam scanning carbon ion radiotherapy for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Maki, K., Haga, H., Katsumi, T., Hoshikawa, K., Kaneko, T., Takahashi, R., Sugawara, S., Koto, M., Motoi, F., and Ueno, Y. (2025). Treatment outcomes in patients receiving carbon-ion radiotherapy versus hepatectomy for hepatocellular carcinoma (\u22654 cm): A retrospective study in Japan. J. Clin. Med., 14.","DOI":"10.3390\/jcm14165678"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000529574","article-title":"Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter proof-of-concept study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1269\/jrr.48.A1","article-title":"Clinical results of carbon ion radiotherapy at NIRS","volume":"48","author":"Tsujii","year":"2007","journal-title":"J. Radiat. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3350\/cmh.2023.0217","article-title":"Carbon ion radiotherapy in the treatment of hepatocellular carcinoma","volume":"29","author":"Byun","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.radonc.2018.10.009","article-title":"A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger","volume":"132","author":"Shibuya","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000520277","article-title":"Efficacy and safety of 4 fractions of carbon-ion radiation therapy for hepatocellular carcinoma: A prospective study","volume":"11","author":"Shibuya","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000526163","article-title":"Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s10147-022-02166-0","article-title":"New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma","volume":"27","author":"Kudo","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.5145","article-title":"Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve","volume":"12","author":"Tomonari","year":"2023","journal-title":"Cancer Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2057892","DOI":"10.1080\/2162402X.2022.2057892","article-title":"Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice","volume":"11","author":"Zhou","year":"2022","journal-title":"OncoImmunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1179064418761639","DOI":"10.1177\/1179064418761639","article-title":"The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules","volume":"11","author":"Arnold","year":"2018","journal-title":"Cancer Growth Metastasis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-\u03b3 production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.radonc.2007.09.010","article-title":"Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer","volume":"85","author":"Cummings","year":"2007","journal-title":"Radiother. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505189","article-title":"A new era in systemic therapy for hepatocellular carcinoma: Atezolizumab plus bevacizumab combination therapy","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/liv.15907","article-title":"Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab","volume":"44","author":"Kikuchi","year":"2024","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12328-024-02030-w","article-title":"Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy","volume":"17","author":"Nakabori","year":"2024","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2169\/internalmedicine.1844-23","article-title":"Hepatocellular carcinoma showing tumor shrinkage due to an abscopal effect","volume":"63","author":"Yano","year":"2024","journal-title":"Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:12:13Z","timestamp":1783933933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":33,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145449"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145449","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}